We’re excited to share highlights from the third Network Meeting and Consortium General Assembly (CGA) of the METHYLOMIC Project, which took place last week in Brussels.
ASPHALION is proud to be the regulatory partner in this ambitious Horizon Europe initiative, which is paving the way toward personalized treatment for Crohn’s disease (CD). Our MedTech Associate Manager, Diego Sanoja, has been actively involved in advancing this groundbreaking project.
At the core of this project is the European OMICROHN Clinical Performance Study, alongside the pivotal EPIPSORA Clinical Trial. These endeavors are pivotal as they strive to clinically validate the predictive power of peripheral blood epigenetic profiles. By doing so, we aim to tailor treatments with approved biologics uniquely suited to individual patients with Crohn’s disease.
A significant highlight of this initiative is a groundbreaking blood test that will undergo clinical validation in a distinguished trial involving 400 Crohn’s disease patients across multiple countries. This test, designed to pinpoint the optimal treatment for each patient, will be compared against a control group receiving conventional treatment methods. The results will be crucial in determining the effectiveness of personalized treatment strategies.
The OMICROHN Trial, which commenced in March 2025, spans across numerous esteemed European hospitals and will extend over three years for comprehensive evaluation. Supported by a generous Horizon Europe grant exceeding 9 million euros, this study exemplifies collaboration across borders, driving forward the future of personalized medicine.
We are immensely proud of our team at ASPHALION for their invaluable contributions, collaboration, and relentless pursuit of innovative healthcare solutions. Stay tuned for more updates as we work towards transforming the landscape of Crohn’s disease treatment!
If you need information or have requests regarding your HORIZON projects, you contact us at: [email protected]
